Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) FCF Margin: 2009-2025

Historic FCF Margin for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to 8.90%.

  • Myriad Genetics' FCF Margin rose 1021.00% to 8.90% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.02%, marking a year-over-year increase of 956.00%. This contributed to the annual value of -3.31% for FY2024, which is 1981.00% up from last year.
  • As of Q3 2025, Myriad Genetics' FCF Margin stood at 8.90%, which was up 215.60% from -7.70% recorded in Q2 2025.
  • Myriad Genetics' 5-year FCF Margin high stood at 37.38% for Q1 2021, and its period low was -32.91% during Q4 2023.
  • Moreover, its 3-year median value for FCF Margin was -10.74% (2023), whereas its average is -10.51%.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by 6,940bps in 2022, then skyrocketed by 3,433bps in 2024.
  • Quarterly analysis of 5 years shows Myriad Genetics' FCF Margin stood at -8.02% in 2021, then slumped by 429bps to -12.32% in 2022, then plummeted by 2,059bps to -32.91% in 2023, then surged by 3,433bps to 1.42% in 2024, then skyrocketed by 1,021bps to 8.90% in 2025.
  • Its FCF Margin stands at 8.90% for Q3 2025, versus -7.70% for Q2 2025 and -11.03% for Q1 2025.